RT Journal Article
SR Electronic
T1 Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1509
OP 1511
DO 10.21873/invivo.13599
VO 38
IS 3
A1 HIRAI, TAKAHIRO
A1 INOMATA, MINEHIKO
A1 MINATOYAMA, SHUHEI
A1 HASHIZUME, MOE
A1 TAKATA, NAOKI
A1 HAYASHI, KANA
A1 SETO, ZENTA
A1 TOKUI, KOTARO
A1 TAKA, CHIHIRO
A1 OKAZAWA, SEISUKE
A1 KAMBARA, KENTA
A1 IMANISHI, SHINGO
A1 MIWA, TOSHIRO
A1 HAYASHI, RYUJI
A1 TANAKA, SHINICHI
A1 NOGUCHI, AKIRA
A1 SATO, TSUTOMU
YR 2024
UL http://iv.iiarjournals.org/content/38/3/1509.abstract
AB Background/Aim: Immune checkpoint inhibitors can induce immune-related adverse events in various organs, thus careful observation is required. Case Report: A 69-year-old man was diagnosed with advanced lung adenocarcinoma and treated with combined therapy of carboplatin plus pemetrexed plus pembrolizumab. After two cycles of treatment, anemia was noted. Myelosuppression due to cytotoxic anticancer agents was suspected and the cytotoxic agents were discontinued, followed by three courses of pembrolizumab monotherapy. However, the anemia persisted, requiring red blood cell transfusions. A bone marrow biopsy revealed erythroblast hypoplasia and chromosomal abnormalities, resulting in a diagnosis of pure red cell aplasia. These adverse events were considered immune-related because of the treatment history with an immune checkpoint inhibitor, and 60 mg/day (1 mg/kg/day) of prednisolone was initiated. Anemia improved, and it did not recur during the tapering of prednisolone. Conclusion: Immune-related pure red cell aplasia should be considered for patients presenting anemia during treatment with immune checkpoint inhibitors.